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HADDOw and Timmis (1953) introduced the sulfonoxy butanes as cancer
chemotherapeutic agents and one of this group of alkylating drugs, Myleran
(1,4-dimethylsulfonoxy butane, CH3-S02-O-CH2.CH2. CH2 CH2-O--S02-
CH3) has been found useftil in the management of chronic granulocytic leukaemia
(Dameshek, Granvilleand Rubio, 1958). BecauseofitsinsolubilityMyleran canonly
be administered orally and its maximal effects on the haemopoietic svstem require
2-3 weeks to develop.
Timmis and Hudson (1958) produced 1,4-dimethyl sulfonox-1,4-ydimethyl
butane (CB. 2348) or dimethyl Myleran:
CH3-SO, -CH.CR2.CH2.CH .- O-S02 CH3
The addition of methyl groups to the terminal carbon atoms in the Myleran mole-
cule changed the mechanism of alkylation from a largely SN2 to an SN1 type and
produced a compound of greater solubility with a quicker onset of action. This
compound is soluble in warm 95 per cent alcohol, and the solution may subse-
quently be diluted to a convenient volume with normal saline. Bierman et al. (1958)
found that this drug in doses of 0-4-0-8 mg./kg. produced remission in chronic
granulocytic leukaemia but had no effect in acute myeloid leukaemia or on solid
tumours.
Rationaile
The management ofmalignant disease ofthe head and neck area in East Africa
presents problems not encountered in more highly developed countries (Clifford,
1961). Radiotherapy is not available, and for patients presenting with growths
unsuitable for surgery or for regional arterial infusion therapy, treatment with
nitrogen mustard was attempted: initially the recommended pharmacopoeial
dose (0.1 mg./kg. body weight, daily for 5 days) was given, but as experience sug-
gested that tumour response was proportional to the dose administered, attention
was directed to the development of methods designed to allow larger doses of the
drug to be given with safety to the patient. It was found that 2:0 mg./kg. HN2
was tolerated if stored autologous bone marrow was used to compensate for mar-
row depression (Clifford, Clift and Duff, 1961). Even with this dose effective pal-
liation was limited to the more anaplastic and lymphomatous growths. Higher
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toxicity before the marrow graft had fully developed. Miller and Lawrence (1961)
developed a method ofprotecting the pelvic bone marrow by temporarily occluding
the abdominial aorta, but noted that a dose of 1 2 mg./kg. HN2 produced 8th nerve
damage. To avoid this and other cerebral complications, the total dose of HN2
was administered as fractions over a three-week period whilst the pelvic marrow
was protected bv occluding the abdominal aorta (Duffet al., 1961). By this method
1.5 to 3 0 mg./kg. HN2 was administered without producing fatal bone marrow
injury, and it was estimated that the effective tunmour dose was slightly less than
doubled above the level of occlusioin. Subsequent studies (Clifford et al., 1963)
showed that 2-5 mg./kg. administered as 0 8, 0 8 and 0 9 mg./kg. over a three-week
period produced complete clinical anid histological remission of disease in thirteen
out ofeighteen patients with anaplastic carcinoma ofthe post nasal space, but only
one remained without recurrence for longer than six months. On attempting to
increase the dosage to a total of 3 0 mg./kg. over a three-week period it was found
that the majority of patients succumbed to cerebral toxicity. Attempts to over-
come this barrier were directed along two lines:
(1) Isolating the brain under hypothermia (6 min. at 29 4° C.) by clamping the
cranial arteries in the neck. Any HN2 still unfixed before unclamping the cranial
arteries could be neutralised by injecting 20 c.c. of a 50 per cent solution ofsodium
thiosulphate, intravenously. The results and complications of this procedure will
be published elsewhere.
(2) By using an alkylating agent which might be less neurotoxic.
(a) Chloramine mustard (methyl-2-chloroethyl-ethylenimonium) a metabolite
of nitrogen mustard was prepared according to the method of Hunt and Philips
(1949). This compound was found to be quite as neurotoxic, and clinically less
effective, in comparable doses to HN2. Of twenty patients with anaplastic carci-
noma ofthe post nasal space treated with 2 4-3 0 mg./kg. chloramine mustard and
abdominal aortic occlusion, ten patients developed a life-threatening degree of
toxicity, and six ofthese succumbed to neurotoxicity. Ofthe fourteen patients who
survived. only three were free of recurrence for longer than one month (Oettgen
et al., 1964).
(b) Dimethyl Myleran probably has a different mechanism of action from the
nitrogen mustards since it does not alkylate nucleophilic centres in aqueous media
at physiological pH because it reacts with water far more readily. The most likely
mechanism therefore is that it acts in the lipid phase, where the chances ofreacting
with an important nucleoplhilic centre such as phosphate in preference to water,
would be much greater. A possible site of action could well be in the lipid protein
interphases within the cytoplasm which are thought to play an important part
in protein synthesis. In addition, Myleran has shown no neurotoxicity in clinical
use and since dimethyl Myleran has behaved similarly in a small number of clinical
experiments we concluded that this drug was now worth trying. This paper
describes the complications and results in treating fifteen patients with advanced
malignant disease of the head and neck with dimethyl Myleran and abdominal
aortic occlusion.
Preparation of dimethyl Myleran solution
In all cases a freshly prepared solution was used. 60 mg. of dimethyl Myleran
were dissolved in 5 ml. of ethyl alcohol, warmed to 50° C., and an aliquot of this
solution was diluted 1: 5 with sterile isotonic saline.
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Method of occlusion
The procedure was carried out in an operating theatre. All patients were
anaesthetised with 0 5 g. Pentothal, paralysed with 120 mg. Flaxedil, intubated
and then maintained on manual positive pressure respiration. A Kidde abdominal
tourniquet, using a 20 cm. cuff, was then applied and inflated to a pressure of 200
mm. Hg. At this pressure mid-torso occlusion is complete (Harries et al., 1963).
The dimethyl Myleran solution was then injected into an arm vein.
Clinical Material
Anaplastic carcinoma of the post nasal space . . . . 12
Reticulum cell sarcomainvolving the postnasal space and cervical glands . 1
Plasmacytoma (solitary occipital) . . . . . . 1
Anaplastic carcinoma mid-third oesophagus . . . . . 1
RESULTS
Data relating to dosage, period ofocclusion, toxicity and response in the fifteen
patients treated are outlined in Table I.
Illustrative Cases
Case No. 2
A female Kipsigis aged 30 years was admitted with an increasing swelling of
the right side ofthe neck ofone year's duration. For two months preceding admis-
sion she had trismus and right ptosis. Examination showed a large tumour in the
post nasal space, with a huge mass of fixed glands in the right side of the neck.
As well as a complete right ptosis she had involvement ofthe right 3rd, 4th and 6th
cranial nerves and a right conductive deafness. X-rays of the base of the skull
showed bone erosion. Biopsies from the post nasal space tumour and the neck
glands were reported as anaplastic carcinoma. There was no evidence of other
organ involvement.
Treatment.-1I0 mg./kg. HN2 was given over three days and repeated after one
month, the last course finishing on D -44. On DI, D6 and D9 she was given 54,
36 and 36 mg. dimethyl Myleran intravenously, each with a ten minute period of
abdominal aortic occlusion (A.A.O.), total dose 126 mg. or 2-5 mg./kg. The patient
was discharged from hospital at her own request on D44 and was readmitted on
D87, by which time the cervical gland mass was larger than on her first admission
and had ulcerated through the skin. In addition to her orbital symptoms she also
had nasal obstruction and severe epistaxis. After her anaemia had been treated by
blood transfusions (4 pints), she was given on D98, D102 and D10, 48, 48 and 36
mg. dimethyl Myleran with A.A.O. On this occasion the occlusion periods were
each ofthirty minutes. Total dose 126 mg. or 2-5 mg./kg.
Toxicity.-No toxicity was evident after HN2. Haematological toxicity to the
first course of dimethyl Myleran was evident on D25-W.B.C.3,000, platelets
130,000. Recovery was evident by D30-W.B.C.5,400, platelets 180,000. After
the secondcourse oftreatmenthaematological toxicitywaswelldevelopedonD116-
W.B.C.1,500, platelets 199,000, reaching a lowest level on D126--W.B.C.1,500,
platelets 15,000. Recovery was slow but was evident by D145-W.B.C.5,200,
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TABLE I.-Summary of the Fifteen cases showing
KEY: t P.N.S. .
t F.U.D.R.
§ Dates .
Post nasal space (nasopharynx).
5 fluorodeoxyuridin.
Dl = 1st day of dimethyl Myleran therapy.
D -1- 1st day previous to dimethyl Myleran therapy.
DIMETHYL MYLERAN TOXICITY (General*)
. _~~~~~~~~~~~~~~~.
Sex and Previous therapy | - |
No. Age Disease and dates Results P o E- 4 Ee =
I II III IV V VI VII VIII IX X XI XII
1 M-14 Anaplastic HN2 1-0 mg./kg. Marked Dl 30 10
carcinoma I.V. August 62 regression D3 30 10 ±2 5 +
P.N.S.1 D6 24 10
HN2 1-0 mg./kg. Marked D61 42 20 )
I.V. Sept. 62 regression D65 36 20 3-5 + + + + +
completed D-44 D69 36 20 J
F-35 Anaplastic
carcinoma
P.N.S.
HN2 1-0 mg./kg.
I.V. August 62
HN2 1-0 mg./kg.
I.V. Sept. 62
completed D-44
Marked
Slight
Dl
D6
D9
D98
D102
D11O
3 M-26 Anaplastic HN2 10 mg./kg. Dl
carcinoma I.V. Slight D4
P.N.S. completed D-32 D7
Anaplastic HN2 1-0 mg./kg. Moderate
carcinoma I.V. subjective
P.N.S. completed D-40 improvement
Dl
D10
54 10
36 10
36 10
48 30
48 30
36 30
48 10
48 10
36 10
60 10
60 10
}2-5
}2.5
}2-5
} 2.0
++ +
++++ + ++±+
+++ +++ +++
2
M-34 4
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dosage, period ofocclusion, toxicity and response
* General Toxicity . + slight.
+ - moderate.
+ + + very severe.
+++ + very severe, for eyes and mouith denotes tulceration for alopecia denotes total.
TOXICITY (Haematological)
C% = :; _ Y =$i:=;Wi;iResponseRemarks
XIII XIV XV XvI XVII XVIII XIX XX
Dl D22 Dl D22 Slight Died D84 from haematological toxicity:
11,000 3,000 250,000 60,000 P.M. showed tumour still present in
P.N.S.
+ ++ + 1)61 D81 D61 D81
12,000 1,600 250,000 30,000 Slight
Dl D25 Dl D25 Moderate. Neck Patient allowed to leavehospitalat own
+ + + + 4 9,000 3,000 270,000 130,000 circumference request. Readmitted D98 with large decreased by 4 cm. growth.
D98 D126 D98 D126 Marked. Neck cir- On D160 developed multiple suibcu-
+ + + ± + + + 7,000 1,500 230,000 15,000 cumference decreased taneouis secondary deposits. Died
by 10 cm. Lasting from carcinomatosis on D181.
to D156 (2 months)
Dl D21 Dl D21 Moderate Proof biopsy D22 histologically posi- + 5,000 3,500 280,000 86,000 tive but P.N.S. tumour markedly (Neutro- reduced in size. Discharged at own
phils 500) request on D30.
Dl D30 Dl D34 Moderate. (Com- Proof biopsy D120 tumour in P.N.S., + ++ +L+ + + 5,500 1,600 150,000 10,000 plete relief of severe histologically positive.
nasal obstruction)
Dl D20 Dl D20 Nonie Oral cytoxan 8 mg./kg. failed to arrest
+ + 7,800 2,600 340,000 200,000 disease. Died D62.
Dl D16 Dl D21 None Died D70 froin bronchopneiimonia + + 9,200 2.000 260,000 105,000 secondary to haematological toxicity.
D50 D68 D50 D65 Slight
+ + + + + + 4,800 850 270,000 46,000
Dl D19 Dl D18 Marked Clinically complete regression. + + + + + 6,000 1,600 230,000 15,000
Dl D33 Dl D40 Marked regression of Proof biopsy D59 neck and P.N.S. + ++ + - 9,500 2,200 210,000 22,000 cervical gland mass positive for tumour.
by 12 cm. on D68
D72 D88 D72 D88 None I Died D89 from haematological toxicity. + + + + + 6,800 1,200 110,000 3,800
Di D23 Dl D23 Marked. Neck Died D26from haematological toxicity. + 4,500 1,600 235,000 27,000 glands reduced by 15 P.M. Tuimour present in liver and post cm. on D18 nasal space. Bowel normal.
Di D21 DI D21 Marked Proof biopsies P.N.S. D92-negative. ++ + 9,000 1,300 300,000 21,000 Repeated D156-negative.
D53 D77 D53 D76 Complete regression
+ + + + + 6,000 1,500 120,000 16,000 of neck gland mass.
Clinically free of
disease
Dl D26 Dl D26 Marked Clinically free of disease but proof + + ± + + ± 6.100 1,500 160,000 26,000 biopsy D53-positive.
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TABLE I.-
I
ISex and
No. Age Disease
I II III
12 M-26 Anaplastic
careinomia
P.N.S.
13 1M-50
14 M-19
1 1-
15 ANI-40
Anaplastic
carcinoma
P.N.S.
Anaplastic
carcinoma
P.N.S.
Previous therapy
and dates
IV
Auiguist 61
Regional
intra-arterial
F.U.D.R-t
February 62
HN2 2-5 mg./kg.
+ A.A.0.
July 62
Chloramine mtustard
1-6mg./kg. A.A.0.
completed D-11 7
Carcinoma oesophagI,s
anaplastic
inid and
lower
oesoph.
Results
V
Marked
regression
Marked
regression
Marked
DIMETHYL MYLERAN
VI VII VIII IX
Dl 48 10 2 0 DIO 48 1
D63 60 30 2 4 D67 60 30 24
Di 48
D2 48
D5 48
Dl 48
D3 48
1)25 48
D36 48
Dl 48
D4 48
D23 48
D32 48
D37 48
60
60
60
60
60
60
60
60
60
60
60
60
}28
}20
}2.0
}3 0
30
TOXICITY (General*)
CZ
C~O _ ,
X I II
xi xi
+ + ++ + + +
++++ +±+ ++++
++±± +-+ -+++
platelets 83,000. She developed total alopecia after the first course of treatment
but oral mucositis was mild and never necessitated tube feeding. These signs of
toxicity were more noticeable after the second course of treatment. On D117
she developed severe ulcerating buccal mucositis, blepharitis, conjunctivitis and
corneal ulceration which persisted for the following three weeks and necessitated
tube feeding.
Response.-The two courses of HN2 had produced marked but not complete
tumour regression and improved her trismus and ptosis. This improvement lasted
for eight weeks. Subsequent to the first course ofdimethyl Myleran tumour regres-
sion was very slight. The response to the second course was more dramatic, the
neck decreasing in circumference by 10 cm. between D98 and D124. This remission
persisted till D156, when regrowth commenced. At this time the patient com-
plained of lower back pain which gradually worsened. Numerous subcutaneous
skin deposits were evident by D160. She died from generalized carcinomatosis on
D181.
Comment.-The significance ofthe difference in tumour response to two courses
oftreatment with equal dosage ofdimethyl Myleran, but with different periods of
aortic occlusion, is discussed below.
Case No. 7
A male Kikuyu, aged 45 years, was admitted to hospital with a large painless
occipital swelling, which had developed over the preceding year (Fig. 1). X-rays
of the skull showed a large central occipito-parietal defect (Fig. 2) and cerebral
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continued
:
aE (1 -,~ ,=1 5- la
C
C.
V;,Q
4- ++ + +
+ + +
++++ +++H
++++- H-H-H
TOXICITY (Haematological)
Xv XVI XVII XVIII
Dl D24 DI D24
10,600 2,000 140,000 40,000
D63 D87 D63 D87
16,000 1,200 205.000 14,000
Dl D9 DI D5
6,700 2,800 190,000 55,000
Dl D13 DI D13
16,600 4,200 350,000 140,000
D250 D36 D25 D31
8,400 7,800 110,000 12,000
Dloo D21_ DI D21
5,900 6,100 178,000 91,000
D23 D30 D23 D36
5,300 4,300 156,000 100.000
Rcsponse
XIX
None
Marked. No evi-
dence of tumour at
post inortem
Marked
Slight
Moderate
Moderate
Remarks
XX
Died D97 while recovering fromii hae-
matological toxicity from subarachiioid
haemorrhage.
Patient discharged at ow,n request on
D41. Declined P.N.S. biopsy. Total
regression of neck glands.
Discharged on D50. Disease still
evident (cervical glands) buit patient
asymptomatic.
Dysphagia commenced to improve on
D26. Took his discharge on D54.
angiography confirmed thatthe growth was extra dural. Histologically the tumour
was composed of plasma cells. Bone marrow aspirations were normal. Bence-
Jones's protein was absent from the urine. Serum phosphorus, calcium, acid and
alkaline phosphatase were normal. Electrophoresis showed a normal plasma
protein pattern. As there was no evidence of myelomatous deposits elsewhere the
tumour was diagnosed as a solitary plasmacytoma.
Treatment. On DI, D3 and D5 the patient was given 48 mg. dimethyl Myleran
intravenously, after the abdominal aorta had been occluded. Total dose 144 mg.
or 2-5 mg./kg. In each instance, occlusion was maintained for ten minutes.
Toxicity
(1) Haematological toxicity was evident by D14, W.B.C.2,850, platelets
125,000, and was maximal at D18-19, W.B.C.1,600, platelets 15,000. Both
sternal and iliac marrow aspirations were extremely hypoplastic and recovery
was slow, commencing on D39.
(2) Severe dysphagia due to buccal mucositis and ulceration developed on D13.
This involved the lips, tongue and soft palate and made tube feeding necessary for
three weeks.
(3) Depilation and madarosis commenced on D16 and during the following week
became complete; coincidental withthese, dark hyperkeratotic areas developed on
the skin ofthe lower face and neck. Depilation persisted till the patient's discharge
from hospital on D66.
1-
l1
l1
l1
l1
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Response.-Tumour regression was apparent by DI7, and this continued till
D57 by which time the tumour had greatly decreased in size. No further reduction
in size was noted thereafter (Fig. 3).
Case No. 10
A female Jaluo, aged 35 years, was admitted with a two year history of head-
ache, pain on the right side ofthe face and neck, and agradually increasing swelling
on the right side ofthe neck. There was proptosis and ptosis ofthe left eye and the
left 3rd, 4th, 5th, 6th and 12th cranial nerves were paralysed (Fig. 4). Though a
tumour was not palpable in the post nasal space, strip mucosa biopsy showed an
anaplastic carcinoma.
Treatment.-On both DI and D14, 36 mg. dimethyl Myleran was given intra-
venously, the abdominal aorta being occluded on Dl for ten minutes and on D14
for twenty minutes. The total dose for this course was 72 mg. or 1-8 mg./kg. A
second course was given on D53, D57 and D67 as 36, 36 and 48 mg. Total dose
120 mg. or 3-5 mg./kg.
Toxicity.-Severe hypotension occurred after each occlusion but this was con-
sidered a manifestation of a cardiodynamic upset. Haematological toxicity was
evident by D16-W.B.C.1,500, platelets 35,000. Recovery was slow, on D30-
W.B.C.2,800, platelets 75,000; on D38-W.B.C.2,900, platelets 110,000, but bv
D48-W.B.C.8,800 and platelets 215,000. After the second course (D53-67)
haematological toxicity was marked, by D77-W.B.C.1,500, D76 platelets 16,000.
Recovery was extremely slow and irregular, i.e. on D139-W.B.C.2,850, platelets
7,000. Alopecia, eventually complete, commenced on D23. Buccal and labial
mucosity and ulceration developed after both courses of therapy, but was most
marked after the second course, lasting from D66 to D89.
Response.-Regression of the cervical gland mass was marked; commencing
on D22 and continuing to D80 when a tumour could notbepalpated. Thepostnasal
space was biopsied on D92 and D156 and both specimens were histologically free of
disease. As a result of therapy the ptosis, proptosis and the left 3rd, 4th, 5th and
6th cranial nerve lesions were cured, but the right 12th lesion persisted. She was
discharged to follow up on D161, at that time free of disease (Fig. 5).
EXPLANATION OF PLATES
FIG. 1. Case No. 7 on admission. Large occipital plasmacytoma.
FIG. 2. Case No. 7. Lateral X-ray of skull showing large posterior cranial defect and greatly
increased vascular markings.
FIG. 3. Case No. 7 on D60. Marked tumour regression following dimethyl Myleran therapy
which has produced total alopecia. The outline of the cranial defect is evident.
FIG. 4. Case No. 10 on admission. Anaplastic carcinoma ofpost nasal space.
FIG. 5. Case No. 10 on D95. Dimethyl Myleran therapy has produced total regression of the
right cervical gland mass and there is no evidence of left orbital involvement. She has total
alopecia and madarosis. A healing labial ulcer is evident on the right lower lip.
FIG. 6. Case No. 15. Barium swallow showing closure of oesophageal lumen by tumour.
FIG. 7. Case No. 15. Barium swallow on D41 after dimethyl Myleran therapy. Patient swal-
lowing a normal diet but tumour still present.
FIG. 10. Case No. 11. Anaplastic carcinoma of post nasal space in a Kikuyu male age 37. Large
left cervical gland mass with left ptosis, and 3rd, 4th and 6th cranial nerve palsy.
FIG. 11. Case No. 11. Clinical regression after dimethyl Myleran therapy. Note complete
alopecia including eyebrows. Healing labial ulceration lower lip.BRITISH JOIURNAJ. OF CANCER.
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Case No. 15
A forty year old male Meru was admitted with a four month history ofincreas-
ing dysphagia, complete for solids, retrosternal pain and severe weight loss. Barium
swallow showed a lesion in the mid and lower oesophagus, and at oesophagoscopy
an ulcerating growth commencing at 35 cm. from the upper alveolar border was
evident (Fig. 6). Biopsy specimen was reported as a poorly differentiated squam-
ous epithelioma.
Treatment.-240 mg. dimethyl Myleran was given intravenously as 48 mg. doses
each on DI, D4, D23, D32 and D37, the abdominal aortic occlusionbeingmaintained
in each instance for one hour.
Toxicity. Haematological toxicity was slight and was entirely confined to a
decrease in the platelets, i.e. D21-W.B.C.6,100, platelets 91,000. On D22 he
developed bucco-labial mucositis and ulceration and tube feeding was necessary
from D25 to D30. On D26 he had severe blepharitis and conjunctivitis ; this
was associated with the appearance of areas of hyperkeratosis mainly affecting
the nose and lower face. He had total alopecia and madarosis by D30.
Response.-Dysphagia commenced to improve on D26 and by D36 he was able
to eat a normal diet (Fig. 7). Oesophagoscopy on D45 showed tumour still presenlt
and thiswas confirmedhistologically. Thepatient was dischargedat his ownrequest
on D54 without dysphagia, declining surgery.
DISCtTSSION
Toxicity
Haematological.-Myleran is widely used in the treatment of chronic granulo-
cytic leukaemia, in which condition it has a high therapeutic index. The conven-
tional dosage employed for such treatment produces toxic effects directed mainly
against the granulocytic and thrombocytic elements of the bone marrow. Elson
(1958) has investigated the haematological effects of members of the Myleran
series of compounds, CH3.802.0. (CH2).0.SO22. CH3 where "n" has varied
from 2 to 8. The blood response curves following single doses of the alkylating
agents showed a characteristic pattern. There was a steady fall of the neutrophils
to a minimum value followed by a progressive recovery. Platelets were also
depressed and thrombocytopenia was often a major factor in causing death in
experimental animals. Dimethyl Myleran was about three times as active as
Myleran in depressing neutrophils and the methylated compound had greater
rapidity of action.
In contrast to the nitrogen mustard series of alkylating agents, drugs of the
Myleran group exhibit only slight lympholytic activity. In none of the cases
reported in this series did the lymphocyte count fall below 1,000 per c.mn.,
whereas extremely low lvmphocyte counts are often obtained using equivalent
doses of nitrogen mustard.
It was soon obvious that aortic occlusion for ten minutes did not protect the
pelvic marrow depots. Fig. S shows the peripheral blood neutrophil counts of four
cases receiving 2o5 mg./kg. of dimethyl Myleran with aortic occlusion for ten
minutes. In each case the neutrophils were depressed to less than 1,000 per c.mm.
and remained at this level for at least ten days. The effect on the platelet count
was still more alarming and is depicted in Fig. 9. In two cases a thrombocytopenia
of less than 50,000 platelets per c.mm. lasted for three weeks. Serial marrow
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aspirations from the sternum and iliac crest were performed in all cases. All the
marrows were extremely hypoplastic and no protection of the pelvic marrow could
be demonstrated.
Prolongation of the periods of occlusion to twenty minutes and thirty minutes
did not lessen the thrombocytopenia. The neutrophil counts fell to low levels but
1-
to
9-
8-
7-
0 5 l0 15 20 25 3_ 5 4
Days after cornmencemnent of therapy
FIG. 8. Changes in the neutrophil count following 2-5 mg./kg. dimethyl Myleran administered
as 3 equal doses on D1, D3 and D5. Period of occlusion 10 minutes.
recovery was quicker than after ten minute occlusions. Serial marrow aspirations
showed parallel depletion of both sternal and iliac crest marrow, but reactivation
of haemopoiesis occurred more quickly in the pelvis than in the sternum. It was
concluded that occlusion for thirty minutes gave some slight protection to pelvic
marrow depots but that this was inadequate.
Occlusion for sixty minutes appeared to protect granulocytopoiesis satisfac-
torily but dangerous thrombocytopenia still occurred. Marrow aspirations in these
cases demonstrated normal granulocyte production in the pelvic marrow, bult
there was a marked reduction ofmegakaryocytes. The reasons for this are obscure.
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Conventional administration ofdimethyl Myleran and ofthe parent drug Myleran
has demonstrated the sensitivity of megakaryocytes to these drugs, but thrombo-
cytopenia in the absence of neutrophil depression has not been reported. Pro-
longed aortic occlusion produces venous stasis within the marrow sinusoids. It is
possible that this potentiates the toxicity of small quantities of unfixed dimethyl
Myleran against the megakaryocytes. We have not been able to design an ethical
experiment to test this possibility.
Erythropoiesis was halted in all cases except those that were occluded for sixty
minutes, and the transfusion requirements exceeded the pre-treatment needs.
300
250
200-
X<oo
0 5 10 15 20 25 30 35 40 45
Days after commencement of theraPY
FIG. 9. Changes in the platelet count following 2-5 mg./kg. dimethyl Myleran administered as
3 equal doses on Dl, D3 and D5. Period of occlusion 10 minutes.
Bucco-labial mucositi8 and ulceration occurred in all cases but with varying
degrees of severity. In four cases, this manifestation of toxicity produced severe
faucal ulceration and tube feeding was necessary because of pain associated with
swallowing. The condition usually developed about fourteen days after the first
injection of dimethyl Myleran but occurred as early as eight days and as late as
twenty-four days after the initial treatment. Mucosity and ulceration persisted
for about three weeks and its course was unaffected by local treatment, fungicides
or high vitamin therapy.
Diarrhoea and vomiting.-This usually developed about eight days after an
occlusion, which suggested a toxic symptom rather than an effect ofthe occlusion.
Stools in all cases were negative for significant pathogens, but careful fluid and
electrolyte control reduced the seriousness of this complication.
Blepharitis and conjunctivitis were noted in eight patients and in two progressed
to corneal ulceration. The development of ocular symptoms was coincident with
oral symptoms and the severity ofthis form oftoxicity was directly related to the
latter, as was the degree offacial cutaneous hyperkeratosis. Local treatment pro-
duced no significant response, but no case developed a residual corneal opacity.
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Alopecia and madarosis were severe in all cases, but regrowth of the hair com-
menced three to four months after treatment had finished.
Neurotoxicity.-None of the fifteen patients treated developed symptoms of
neurotoxicity.
Periods of occlusion
As will be noted from Table I it became apparent early in this investigation that
a ten minute period of occlusion was not sufficient to protect the pelvic marrow
depots. This has been fully discussed in the section on haematological toxicity. It
was originally thought that the halflife ofdimethyl Myleran was shorter than that
of nitrogen mustard (HN2) and that a ten minute period of occlusion would be
adequate, but subsequent determinations by W. Davis (1962, personal communica-
tion) have given results of the order oftwenty minutes. Of additional significance
is the fact that dimethyl Myleran is a SN1 type reactor and as such has a slower
rate offixation than the SN2 type reactors such as HN2. The consequences ofthese
differences are not confined to haematological toxicity as related to varying periods
ofocclusion; the effective tumour dose is lowered ifthe circulating drug above the
level of occlusion has not been fixed when the occluding tourniquet is released.
This is well demonstrated in Cases 2 and 12. Case 2 received two courses each of
2f5 mg./kg. dimethyl Myleran. For the first course the periods of occlusion were
ten minutes and only moderate tumour response was noted, whereas the occlusions
for the second course were thirty minutes and a very marked regression ensued.
The pattern of response was similar in Case 12. Eight courses of therapy using
occlusion periods of ten minutes were completed, and each produced severe
haematological toxicity. Three courses using a twenty minute period of occlusion
produced severe haematological toxicity. Increasing the occlusion period to thirty
minutes in four cases did not diminish the incidence of haematological toxicity.
Consequently it was decided that a significantly longer period of occlusion was
necessary. The possible complication of prolonged intestinal ischaemia (Marston,
1962) suggested that the intestinal tract should be sterilized before applying an
occlusion for a sixty minute period. Twelve occlusions, each lasting for sixty
minutes, have been used. In the first two courses sterilization of the intestinal
tract was attempted using Chlorostrep; subsequently this was not considered
necessary. No neurological orothersideeffects attributable to the prolongedperiod
of occlusion were noted. Haematological toxicity was diminished after the one
hour occlusion periods and is discussed above.
Tumour response in different malignancies
Anaplastic carcinoma of the post nasal space.-Twelve cases with this disease
(1-4, 6, 8-14) were treated with dimethyl Myleran and abdominal aortic occlusion.
Four cases (1-4) had received previous therapy with HN2 administered as 1-0
mg./kg. intravenously over three days with minimal toxicity and slight to moder-
ate tumour regression. Subsequent therapy with dimethyl Myleran administered
as 2 5-3 5 mg./kg. with abdominal aorticocclusionproducedmarkedhaematological
and buccal toxicity, with moderate tumour regression.
One case (12) had received two previous courses of therapy, i.e. 2-5 mg./kg.
HN2 with A.A.O. and 1-6 mg./kg. chloramine mustard with A.A.O., each ofwhich
produced marked tumour regression. Treatment with 2-0 mg./kg. diethyl Myleran
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withtenminute occlusionsproducedmuchtoxicitybutnoregression. Asubsequent
course of 2-4 mg./kg. with thirty minute occlusion produced marked tumour
regression but fatal haematological toxicity. Tumour was not evident on post
mortem examination.
Twelve patients with anaplastic carcinoma ofthe post nasal space were treated,
in seventhe response was classified asmarked (Fig. 10 and 11), inthree as moderate,
in one as slight, and one case showed no response (vide Table I).
In no instance was the clinical response to dimethyl Myleran superior to that
attained with comparable doses of nitrogen mustard (Clifford et al., 1963), and of
the twelve patients treated only one was discharged histologically free of disease
(Case 10).
Reticulum cell sarcoma.-One case was treated (Case 5). Previous treatment
with 1.0 mg./kg. HN2 had produced slight regression. Treatment with dimethyl
Myleran, 2'5 mg./kg. and occlusion for ten minutes produced no anti-tumour effect.
Subsequent therapy with oral Cytoxan was also ineffective.
Solitary occipitalplasmacytoma. One patient (Case 7) was treated and has been
discussed. An almost identical case of occipital plasmacytoma had complete
regression with nitrogen mustard 2-5 mg./kg. and A.A.O.
Conclusions
Dimethyl Myleran administered with abdominal aortic occlusion requires an
occlusionperiodofatleast sixtyminutesfor complete drugfixation. Theabdominal
aorta can, with safety, be occluded for sixty minutes.
Dimethyl Myleran administered in the dosages, and with the technique,
described is free from neurological toxicity, but bucco-labial mucositis andulcera-
tion, blepharitis and conjunctivitis, thrombocytopenia, madarosis and alopecia
are common, and may be serious complications with this form of therapy.
The upper safe limit ofdosage for dimethylMyleran administered intravenously
without marrow protection is less than 2-0 mg./kg.
Eight out of the fifteen cases treated had marked tumour regression, and one
was discharged from hospital histologically free of disease.
SUMMARY
1. Fifteen cases of advanced malignant disease were treated with high doses of
dimethyl Myleran and abdominal aortic occlusion.
2. The complications and results ofthis form of therapy are described, and the
toxicity of dimethyl Myleran discussed.
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